VIOLA ADVISORY |
|
CLICK IMAGES TO DOWNLOAD REPORTS
IMMUNOGEN (IMGN): MIRVETUXIMAB SHOWS PROMISE IN 2ND LINE TREATMENT OF PLATINUM-RESISTANT OVARIAN CANCER
|
NEKTAR THERAPEUTICS (NKTR): BEMPEGADESLEUKIN POTENTIAL 1ST LINE TREATMENT IN METASTATIC MELANOMA
|
MORPHOSYS (MOR): TAFASITAMAB AN EFFECTIVE TREATMENT OPTION IN R/R DLBCL
|
3Q19
|
LARGE-CAP PHARMA/BIOTECH
Source: Yahoo Finance, YCharts.com and Viola Advisory, LLC
BIOTECH SMIDs
Source: Yahoo Finance, YCharts.com and Viola Advisory, LLC
DRUG SUPPLY CHAIN2Q18
|